SELLAS Life Sciences Group, Inc. (SLS)
| Market Cap | 82.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.54M |
| Shares Out | 8.42M |
| EPS (ttm) | -3.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $5.80 |
| Previous Close | $5.94 |
| Change ($) | -0.14 |
| Change (%) | -2.36% |
| Day's Open | 5.95 |
| Day's Range | 5.64 - 6.05 |
| Day's Volume | 778,640 |
| 52-Week Range | 1.53 - 17.66 |
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe -
Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are sear...
- Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks and 100% Pr...
- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing -
NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme...
Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant...
– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment –
SLS stock is surging today as investors grow interest in a cancer vaccine from SELLAS Life Sciences in the wake of a rally in GLSI stock. The post SLS Stock: Why SELLAS Life Sciences Is Surgin...
- SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties -
- Received IM PD A pproval to C ommence E nrollment in France for P ivotal Phase 3 S tudy of G alinpepimut -S in A cute M yeloid L eukemia P atients -
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS ) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the deve...
- Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market - - Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track, with m...
Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developm...
Ongoing Clinical Trials Continue to Progress Ongoing Clinical Trials Continue to Progress
NEW YORK, April 28, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo...
NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo...
Preliminary data show 11-fold increase in CD8 cytotoxic T-lymphocytes immune response in patients who received single dose of NPS compared to baseline Preliminary data show 11-fold increase in...
NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo...
SELLAS Positive Trial Data, And Other News: The Good, Bad And Ugly Of Biopharma
- Final analysis shows statistically significant median overall survival of 21 months in patients who received GPS compared to previously reported 5.4 months in the control arm (p-value < 0.0...
Regulatory clarity on registration-enabling Phase 3 study design of NPS in combination with trastuzumab in TNBC patients in the adjuvant setting enhances business development efforts Regulator...
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develop...
- Former Klus Pharma and Actinium Pharmaceuticals Executive Brings Extensive Clinical Development Experience in Hematology-Oncology - - Former Klus Pharma and Actinium Pharmaceuticals Executiv...
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develop...
-- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late...
- Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on November 8, 2019 - - Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on November 8, 2019 -
About SLS
SELLAS Life Sciences Group, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials ... [Read more...]
| Industry Biotechnology | Founded 2012 |
| CEO Dr. Angelos M. Stergiou M.D., ScD h.c. | Employees 5 |
| Stock Exchange NASDAQ | Ticker Symbol SLS |
Analyst Forecasts
According to 2 analysts, the average rating for SLS stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 72.41% from the latest price.